The global human microbiome market is expected to witness significant growth due to increasing awareness towards healthy lifestyle, increasing demand for safe and effective medication, high number of patients with gastrointestinal diseases, inflammatory bowel diseases, obesity and cancer. The regulatory bodies are supporting the growth of market by providing designations and grants for speeding up the drug development process. Orphan drug designation and breakthrough therapy designation was given to RBX2660, a Rebiotix Inc. drug candidate and SER-109, a Seres Therapeutics Inc. drug candidate for the treatment of clostridium difficile infection. In January 2016, a grant was awarded to Epibiome from Bill & Melinda Gates Foundation for microbiome.
The pipeline of human microbiome is very rich with more than 70 drugs. The pharmaceutical companies are focusing towards drug development process in several therapeutic areas such as infectious disease, gastrointestinal, metabolic disorders, central nervous system, ophthalmology, dermatology and oncology. The pharmaceutical companies are using advanced technologies such as Microbiome Isolates and Novel Extracts (MiNE), a Quorum Innovations’ drug discovery technology platform and Specifically Targeted Antimicrobial Peptides (STAMP) technology, a C3 Jian, Inc.’s proprietary platform technology.
Microbiome refers to the collection of microbes and their interaction with the human body. It plays an important role in human physiology and disease. The microbes and their interaction with the human body show the various aspects of human biology. Human body possesses number of different species, particularly bacteria and fungi which help in digesting food, preventing infections, and to perform numerous life-supporting tasks. Microbiome and metagenome have important functions in health and disease of human and their exploration would help to further explore large information in human genetics.
A large number of pharmaceutical companies are coming forward to exploit the market of human microbiome. However, certain factors such as dearth of extensive research and lack of awareness about the efficient use and effects of prebiotic and probiotics among the population are expected to hamper the global human microbiome market growth to some extent.
Geographically, Europe is expected to be the main attraction of the human microbiome market during the forecast period. The region contributed largest share to the global market in 2015. The increasing awareness amongst population for prebiotics and probiotics are the major factors driving the growth of the European human microbiome market. North America market is expected to have lower share in the global market as there is comparatively low awareness regarding the benefits of probiotics and prebiotics.
Some of the key players operating in the global market are Synthetic Biologics, Inc., Enterome Bioscience S.A., Vedanta Biosciences, Inc., Yakult Honsha Co., Ltd., C3 Jian, Inc., ViThera Pharmaceuticals Inc., Second Genome Inc., MicroBiome Therapeutics LLC, AOBiome, LLC, Rebiotix, Inc., and Metabiomics Corporation.